Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Study predicts good passive immunotherapy donors to combat COVID-19on January 19, 2021 at 10:09 am
A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.
- Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMBon January 19, 2021 at 8:55 am
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low.
- Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapyon January 19, 2021 at 8:31 am
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs™ cellular immunotherapy. In a series ...
- Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officeron January 18, 2021 at 9:54 pm
NexImmune today announced the appointment of Dr. Robert (Bob) Knight as Chief Medical Officer (CMO). Dr. Knight is a seasoned executive with extensive experience leading early- and late-stage ...
- New study identifies opposite roles of sugars and fat on cellular immunotherapy of canceron January 17, 2021 at 9:00 pm
The team led by Bruno Silva Santos, Principal Investigator iMM, discovered that the functions of a subtype of white blood cells - gamma delta T cells - are regulated by metabolic resources, namely ...
- Study may help develop more effective personalized immunotherapy for cancer patientson January 14, 2021 at 10:01 pm
New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective ...
- Uma Thurman invests in cancer immunotherapy companyon January 13, 2021 at 11:04 am
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston R&D hub last year, has attracted high-profile investors for its $30 million Series B round.
- New humanized mouse model provides insight into immunotherapy resistanceon January 12, 2021 at 2:03 am
Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has ...
- Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapyon January 11, 2021 at 6:49 am
French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.
- Cancer Immunotherapy Market Analysis with Key Players, Applications, Trends and Forecasts to 2025on January 11, 2021 at 3:45 am
Global Cancer Immunotherapy Market is anticipated to grow at a CAGR of around 13% during 2020-25. Cancer immunotherapy has its extensive utilization in the treatment of blood cancer, prostate cancer, ...
via Bing News